Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Taiwan University Hospital
About this trial
To evaluate the efficacy and safety of intravenous lidocaine in reducing diaphragmatic contraction and suppressing the cough reflex during pulsed field ablation procedures.
Eligibility criteria
Qualifiers
Patients with paroxysmal or persistent AF and are scheduled to undergo PVI.
Patients who can understand the study aims and protocol and are willing to follow the protocol for one year.
Disqualifiers
Informed consent could not be obtained
Known allergy to study drug lidocaine.
Presence of thrombus in the LA or LA appendage
Underlying significant pulmonary disease, such as asthma or COPD needing long term maintenance therapy or documented interstitial lung disease
Trial design
Treatments tested in this trial
- lidocaine
- Saline
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
National Taiwan University Hospital
Lead sponsor
Johnson & Johnson
Collaborator
Source ClinicalTrials.gov